| Company Name: | Abaxis, Incorporated | | Ticker Symbol: | ABAX | | | WWW Address: | www.abaxis.com | | CEO: | Clinton H. Severson | | No. of Employees: | 339 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 22.56 |  -0.02 | 22.53 | 23.29 | 22.39 | 22.76 | 22.35 | 136869 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 496.8 | 22.0 | 1.18 | 0.54 | 0.00 | 38.9 | 0.0 | 29.80 - 11.66 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 22.56 | $ | | PE Ratio - LTM | 38.9 | |
| Market Capitalisation | 496.8 | mil |
| Latest Shares Outstanding | 22.0 | mil |
| Earnings pS (EPS) | 0.54 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 311,392 | $ |
| Effective Tax Rate | 37.0 | % |
| Float | 18.7 | mil |
| Float as % of Shares Outstanding | 85.1 | % |
| Foreign Sales | 18 | mil |
| Domestic Sales | 88 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 8.30 | % |
| Gross Profit Margin | 61.7 | % |
| EBITDA Margin | 21.8 | % |
| Pre-Tax Profit Margin | 18.5 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | 8.4 | % |
| Return on Equity (ROE) | 9.5 | % |
| Return on Capital Invested (ROCI) | 9.5 | % |
| Current Ratio | 7.2 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 4.44 | $ |
| Cash pS | 2.34 | $ |
| Book-Value pS | 6.18 | $ |
| Tangible Book-Value pS | 5.96 | $ |
| Cash Flow pS | 0.81 | $ |
| Free Cash Flow pS | 0.62 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.65 | |
| Price/Tangible Book Ratio | 3.79 | |
| Price/Cash Flow | 27.7 | |
| Price/Free Cash Flow | 36.7 | |
| P/E as % of Industry Group | 176.0 | % |
| P/E as % of Sector Segment | 21.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.7 | 99 | 971 | 4,373 |
| 4 Weeks | 26.10 | 22.35 | 25.81 | -12.6 | 86 | 1,638 | 32,764 |
| 13 Weeks | 29.80 | 22.35 | 27.79 | -18.8 | 76 | 1,721 | 110,127 |
| 26 Weeks | 29.80 | 16.61 | 16.86 | 33.8 | 109 | 2,102 | 266,998 |
| 52 Weeks | 29.80 | 11.66 | 12.47 | 80.9 | 133 | 2,519 | 632,381 |
| YTD | 29.80 | 13.24 | - | 40.7 | 116 | 2,516 | 566,007 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 23.23 | 23.07 | 25.27 | 22.46 | 20.98 | 1.18 | 1.14 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 16.70 | 93.6 | 9.90 |
| Income | 6.38 | 6.2 | 8.82 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 32.51 | NA | 31.59 |
| R&D | 11.85 | NA | 13.04 |
| Normalized Inc. | 4.22 | NA | 7.89 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 14.6 | 9.3 | 5.0 |
| Earnings % | 14.5 | -3.0 | -3.9 |
| EPS % | 14.8 | -6.7 | -3.6 |
| EPS $ | 0.04 | -0.01 | -0.02 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 72.36 |
| Current Ratio | 9.8 |
| Quick Ratio (Acid Test) | 8.0 |
| Liquidity Ratio (Cash) | 6.06 |
| Receivables Turnover | 4.9 |
| Average Collection Period | 73 |
| Working Capital/Equity | 80.2 |
| Working Capital pS | 4.63 |
| Cash-Flow pS | 0.75 |
| Free Cash-Flow pS | 0.30 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 23.81 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 9.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1.8 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.19 |
| Tobin's Q Ratio | 3.53 |
| Current P/E Ratio - LTM | 38.90 |
| Enterprise Value (EV)/EBITDA | 19.77 |
| Enterprise Value (EV)/Free Cash Flow | 79.70 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.79 |
| Price/Book Ratio - LTM | 3.65 |
| Price/Cash Flow Ratio | 27.7 |
| Price/Free Cash Flow Ratio - LTM | 36.7 |
| Price/Sales Ratio | 4.39 |
| P/E Ratio (1 month ago) - LTM | 42.4 |
| P/E Ratio (26 weeks ago) - LTM | 31.2 |
| P/E Ratio (52 weeks ago) - LTM | 22.3 |
| 5-Y High P/E Ratio | 108.4 |
| 5-Y Low P/E Ratio | 18.8 |
| 5-Y Average P/E Ratio | 46.3 |
| Current P/E Ratio as % of 5-Y Average P/E | 84 |
| P/E as % of Industry Group | 176.0 |
| P/E as % of Sector Segment | 21.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 38.9 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.53 |
| Tangible Book Value pS - LTM | 5.96 |
| Book Value pS - LTM | 6.18 |
| Capital Invested pS | 5.76 |
| Cash pS - LTM | 2.34 |
| Cash Flow pS - LTM | 0.81 |
| Free Cash Flow pS - LTM | 0.62 |
| Earnings pS (EPS) | 0.54 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 6.33 |
| Free Cash Flow Margin 5YEAR AVG | 8.91 |
| Net Profit Margin | 11.4 |
| Net Profit Margin - 5YEAR AVRG. | 11.3 |
| Equity Productivity | 0.83 |
| Return on Equity (ROE) | 9.5 |
| Return on Equity (ROE) - 5YEAR AVRG. | 10.4 |
| Capital Invested Productivity | 0.83 |
| Return on Capital Invested (ROCI) | 9.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 10.4 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | 8.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | 9.0 |
| Gross Profit Margin | 61.7 |
| Gross Profit Margin - 5YEAR AVRG. | 58.5 |
| EBITDA Margin - LTM | 21.8 |
| EBIT Margin - LTM | 18.5 |
| Pre-Tax Profit Margin | 18.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 17.9 |
| Effective Tax Rate | 37.0 |
| Effective Tax Rate - 5YEAR AVRG. | 36.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 221 |
| Revenue per Employee | 311,392 |
| Net Income per Employee | 35,437 |
| Average Collection Period | 75 |
| Receivables Turnover | 4.9 |
| Day's Inventory Turnover Ratio | 146 |
| Inventory Turnover | 2.5 |
| Inventory/Sales | 14.9 |
| Accounts Payble/Sales | 3.75 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 1.04 |
| Fixed Assets Turnover | 3.86 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 2.14 |
| Revenue per $ Plant | 7.13 |
| Revenue per $ Common Equity | 0.83 |
| Revenue per $ Capital Invested | 0.83 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 30.6 |
| Research & Devlopment (R&D) as % of Revenue | 7.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.9 |
|
|  
|
| |
 |  |